Valuation: LB Pharmaceuticals Inc

Market Cap 1.19B 1.05B 976M 888M 1.68B 112B 1.7B 11.74B 4.6B 58.7B 4.45B 4.35B 187B P/E 2026 *
-6.44x
P/E 2027 * -6.97x
Enterprise Value 806M 716M 664M 604M 1.14B 76.49B 1.16B 7.98B 3.13B 39.91B 3.02B 2.96B 127B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
99.76%
Yield 2026 *
-
Yield 2027 * -
1 day+0.14%
1 week-1.29%
Current month-4.27%
1 month-13.70%
3 months+20.10%
6 months+29.92%
Current year+65.05%
1 week 33.88
Extreme 33.8833
37.43
1 month 33.13
Extreme 33.13
43.4
Current year 18.43
Extreme 18.43
50.16
1 year 14.32
Extreme 14.3166
50.16
3 years 13.36
Extreme 13.36
50.16
5 years 13.36
Extreme 13.36
50.16
10 years 13.36
Extreme 13.36
50.16
Manager TitleAgeSince
Chief Executive Officer 53 19/11/2024
Director of Finance/CFO 52 02/09/2026
Chief Tech/Sci/R&D Officer 54 14/09/2026
Director TitleAgeSince
Director/Board Member 76 01/07/2019
Director/Board Member 53 01/08/2023
Director/Board Member 53 19/11/2024
Date Insider Type Main position Quantity % Market Cap. Importance
09/10/26 Free

Chief Financial Officer

200,000 0.8911%
09/10/26 Free

Chief Technology Officer

200,000 0.8911%
30/07/26
Deep Track Capital LP
BuyCompany 286,205 0.8872%
Change 5-day change 1-year change 3-year change Capi.($)
+0.14%-1.29%+124.02% - 1.19B
-6.60%-8.56%+42.79%+64.16% 65B
-4.09%-0.11%+2.31%+54.81% 51.19B
+0.03%+5.56%+10.18%+41.75% 51.2B
-1.53%+2.70%+29.72%+34.13% 43.93B
-1.34%+4.12%+16.05%+112.18% 41.96B
-5.97%-6.22%+258.21%+421.57% 38.14B
+6.53%+8.02%+15.74%+53.94% 33.24B
-0.90%-10.49%+31.48%-1.63% 25.2B
-2.76%-9.54%-16.53%-9.55% 22.03B
Average -1.65%-1.63%+51.40%+85.71% 37.31B
Weighted average by Cap. -2.29%-1.21%+43.82%+88.58%

Financials

2026 *2027 *
Net sales - -
Net income -178M -158M -147M -134M -252M -16.91B -256M -1.76B -692M -8.82B -669M -654M -28.13B -201M -179M -166M -151M -284M -19.09B -289M -1.99B -781M -9.96B -755M -739M -31.75B
Net Debt -379M -337M -313M -284M -537M -36B -545M -3.76B -1.47B -18.79B -1.42B -1.39B -59.89B -479M -426M -395M -359M -678M -45.48B -689M -4.75B -1.86B -23.73B -1.8B -1.76B -75.66B
Projected Income Statement - Annual - LB Pharmaceuticals Inc
Logo LB Pharmaceuticals Inc
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. The Company is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a Phase III-ready oral, small molecule for the treatment of acute schizophrenia, defined as a sudden and severe episode of psychotic symptoms, characterized by hallucinations, delusions, and other positive symptoms. The Company is also developing a long-acting injectable, or LAI, formulation of LB-102, which improves compliance, a common issue in patients with schizophrenia and bipolar disorder.
Employees
49
Date Price Change Volume
16/10/26 $36.74 +0.14% 724,805
15/10/26 $36.69 +7.91% 976,646
14/10/26 $34.00 -2.27% 362,714
13/10/26 $34.79 -3.17% 296,790
12/10/26 $35.93 -3.47% 491,509
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
MarketScreener Ratings - LB Pharmaceuticals Inc
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
36.74USD
Average target price
58.00USD
Spread / Average Target
+57.87%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - LB Pharmaceuticals Inc
  1. Stock Market
  2. Stocks
  3. LBRX Stock